Showing results (21-30 of 61) with videos related to
Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
Benzoyl 2-methyl indoles as selective PPARgamma modulatorsJohn J Acton, Regina M Black, A Brian Jones, et al.Cell Metabolism|September 10, 2013
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetesGregory Gaich, Jenny Y Chien, Haoda Fu, et al.Journal of Inherited Metabolic Disease|May 5, 2022
Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophyPierre-Axel Monternier, Jaspreet Singh, Parveen Parasar, et al.The Journal of Biological Chemistry|January 16, 2008
Identification and characterization of a major liver lysophosphatidylcholine acyltransferaseYang Zhao, Yan-Qun Chen, Tabetha M Bonacci, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Phenylacetic acid derivatives as hPPAR agonistsConrad Santini, Gregory D Berger, Wei Han, et al.The Lancet. Gastroenterology & Hepatology|September 24, 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a studyKenneth Cusi, Naim Alkhouri, Stephen A Harrison, et al.Diabetes|July 30, 2002
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonistsGuoqiang Jiang, Qing Dallas-Yang, Zhihua Li, et al.The Journal of Pharmacology and Experimental Therapeutics|June 28, 2022
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked AdrenoleukodystrophyPierre-Axel Monternier, Parveen Parasar, Pierre Theurey, et al.Journal of Hepatology|February 22, 2023
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Stephen A Harrison, Carole Thang, Sébastien Bolze, et al.Endocrinology|May 27, 2006
Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonismRaynald Bergeron, Jun Yao, John W Woods, et al.Pageof 7